John McKearn, Joe DeRisi, Tom Tuschl, Greg Hannon, Evan Eichler, Kevin Shokat, and Stephen Quake | GenomeWeb

John McKearn has been promoted to CEO of Kalypsys, the San Diego-based company said last week.

McKearn joined the company in 2003 as chief scientific officer and became Kalypsys’ president in 2004. Prior to his employment with Kalypsys, he was senior vice president of research at Pharmacia. He has also held senior positions at G.D. Searle, the pharmaceutical subsidiary of Monsanto, Kalypsys said. McKearn holds a PhD in immunology from the University of Chicago and a bachelor’s degree from Northern Illinois University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.